Key facts
- This page summarizes Stephen Hoge's Form 4 filing for Moderna, Inc. (MRNA).
- 5 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 16 Jul 2026, 16:45.
Stephen Hoge - 15 Jul 2026 Form 4 Insider Report for Moderna, Inc. (MRNA)
- Reporting relationship
- President
- Issuer ticker
- MRNA
- Reported as of
- 15 Jul 2026
- Net transaction value
- -$3,605,514
- SEC form
- 4
- Accepted by SEC
- 16 Jul 2026, 16:45:38 UTC
- Prior SEC filing
- 17 Jun 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Dillon, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Stephen Hoge filed Form 4 for Moderna, Inc. (MRNA) on 16 Jul 2026.
Change
- Previous filing in this sequence was filed on 17 Jun 2026.
- Current net transaction value: -$3,605,514.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001760669
Primary reporting owner
Hoge Stephen
- Relationship
- President
- Address
- C/O MODERNA, INC., 325 BINNEY STREET, CAMBRIDGE
- Signature
- /s/ James Dillon, as Attorney-in-Fact
- Signature date
- 16 Jul 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +37,226
- Change %
- +2.5%
- Price
- $19.15*
- Shares after
- 1,521,074
- Date
- 15 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +16,110
- Change %
- +1.1%
- Price
- $19.15*
- Shares after
- 1,537,184
- Date
- 15 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
transaction
Common Stock
Sale
- Transaction value
- $3,605,514
- Shares
- -53,336
- Change %
- -3.5%
- Price
- $67.60
- Shares after
- 1,483,848
- Date
- 15 Jul 2026
- Ownership
- Direct
- Footnotes
- F1
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 4,116
- Date
- 15 Jul 2026
- Ownership
- By Valhalla, LLC
MRNA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 151,933
- Date
- 15 Jul 2026
- Ownership
- By Trust
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -37,226
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,226
- Exercise price
- $19.15
- Footnotes
- F1, F3
MRNA
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -16,110
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 15 Jul 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 16,110
- Exercise price
- $19.15
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 3 footnotes
Footnote F1
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on November 13, 2025.
Footnote F2
These shares are owned directly by a trust for the benefit of Dr. Hoge's spouse and children, of which his spouse is a trustee. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.
Footnote F3
This option is fully vested and exercisable.